Millions of candidate molecules are sifted through by classical computers before pharmaceutical researchers even begin lab synthesis, a process that emphasises the substantial computational power already applied to early drug discovery. Diraq contends quantum computers must be both economical and deployable to achieve true utility, as the pharmaceutical pipeline progresses from a “target-to-hit” stage to a “hit-to-lead” stage where most candidates are quickly discarded. The potential value, the company suggests, lies in making better decisions earlier in the process.
Quantum Chemistry Limits Impact Drug Discovery Economics
Early assessments of quantum computing’s potential in drug discovery, dating back to 2010, already highlighted the need for practical value alongside theoretical capability. Diraq’s calculations indicate that even a utility-scale quantum computer might struggle to serve more than a handful of drug programs simultaneously, meaning the technology must deliver value early in the process to affect overall costs, the company says. A slightly more accurate prediction in molecular modeling, while not on its own, can significantly reduce the risk of pursuing unsuccessful candidates through expensive later stages.
The economics of quantum computing hardware present a further challenge; support systems like refrigeration, lasers, and vacuum systems represent the largest cost component, remaining relatively constant regardless of qubit count. “Those support systems cost the most, and they cost roughly the same no matter how many qubits are inside,” according to the source material, highlighting a fundamental constraint on cost reduction. Protecting intellectual property also complicates deployment; pharmaceutical companies invest heavily in proprietary biological insights and are cautious about sharing data with external computing resources.
These investments are reliant on maintaining competitive advantage for up to a decade, the time it takes for a drug to reach the market. “Few decisions are harder than choosing between technologies that are all improving rapidly and whose ultimate impact remains uncertain,” the source states, emphasizing the difficulty of adopting unproven technologies in a risk-averse industry.
2010 Eli Lilly Analysis: Cost of Clinical Trial Failure
An analysis completed in 2010 by Eli Lilly researchers revealed that improving clinical trial success rates by just 10% across all three phases could reduce the capitalized development costs of a new medicine by over US$600 million, a substantial portion of the then-estimated US$1.78 billion total. This finding emphasised the disproportionate economic benefit of identifying and discarding weak drug candidates early in the development pipeline, before significant resources are committed to experimentation and human trials.
The study systematically varied parameters throughout the drug development process to determine which improvements would have the greatest impact on overall costs, ultimately pinpointing early-stage success as the most valuable area for investment. The 2010 model highlighted that preventing failures in the initial stages of drug development offered a greater return than incremental improvements later in the process, potentially allowing companies to reinvest savings into developing 50% more new medicines.
This emphasis on early-stage efficacy is particularly relevant to the potential application of quantum computing, as the economic advantage hinges on making better decisions before substantial investment occurs. Despite advances in quantum hardware, the economic realities of deployment remain a significant hurdle, as the support systems required for operation often outweigh the cost of the qubits themselves. Deloitte’s 2025 analysis reported an average cost of approximately US$2.23 billion per asset in 2024.
The 2010 study suggests that a 10% improvement in clinical trial success is a worthwhile goal. But it does not guarantee that quantum computing will be the means to achieve it, given the substantial infrastructure costs and the need for high use to drive down the effective cost per program. The focus must shift from proving what quantum computers can do to demonstrating how they can deliver tangible cost savings in a field where avoiding failure is paramount.
Diraq’s Scalable Qubit Architecture Reduces Quantum Computing Costs
Diraq’s silicon spin-qubit architecture directly addresses the economic hurdles facing quantum computing deployment within pharmaceutical research, offering a path toward tighter integration with existing classical computing infrastructure. Unlike superconducting or trapped-ion systems averaging US$26 million and US$19 million respectively, Diraq’s approach aims for cost-effectiveness through compatibility with established semiconductor manufacturing processes, potentially lowering the barrier to entry for widespread adoption. This design prioritizes higher use rates, which directly translate into a lower effective cost per program and improved platform economics, a critical consideration for businesses evaluating quantum investments.
This figure represents a substantial increase from the US$1.78 billion baseline used in a 2010 model, highlighting the growing financial pressures within the industry and the heightened expectations for quantum computing’s potential return on investment. Diraq’s architecture is specifically engineered with this deployment model in mind, recognizing that the ultimate value proposition hinges on delivering tangible cost savings throughout the drug discovery pipeline, according to the company. The company’s strategy centers on building quantum computers using techniques similar to those employed in manufacturing conventional server chips, a move intended to streamline production and reduce overall system costs.
This approach is predicated on the belief that a quantum computer built with familiar methods will be more readily integrated into existing workflows and data centers, accelerating the realization of practical benefits. “With a quantum computer built the way the chips in today’s servers are built, the answer is a resounding yes,” the company states, referring to the potential for positive economic impact. Diraq recently deployed the world’s first silicon spin quantum computer inside a commercial data center, a step intended to demonstrate the viability of this architecture and its potential to reshape pharmaceutical research.
Protecting Proprietary Data Drives On-Premise Quantum Deployment
The pharmaceutical pipeline itself operates as a funnel, beginning with identifying a disease-related protein and then searching for a molecule that interacts with it effectively, a stage known as This initial search is followed by the “hit-to-lead” stage, where most candidate molecules are discarded, highlighting the need for quantum computing to deliver advantages early in the process to impact both cost and time. Companies prioritize maintaining control over their intellectual property, creating a strong preference for deploying quantum computers within their existing data centers rather than relying on external infrastructure for sensitive calculations. This approach allows organizations to enforce their data security policies and compliance procedures while using quantum-enhanced workflows.
Diraq’s silicon spin-qubit architecture is specifically designed to facilitate this on-premise deployment model, prioritizing compactness and compatibility with existing infrastructure to enable tightly integrated quantum-classical computing, the firm reports. The escalating costs of drug development, at US$2.23 billion per asset in 2024, represent a substantial increase from the US$1.78 billion baseline established in 2010.
Pharma companies require confidence that quantum calculations will generate sufficient value to justify investment, and the core argument for adopting the technology remains consistent with any other enabling technology in drug discovery: can it improve decision-making to yield better medicines tomorrow? The company’s recent deployment demonstrates a commitment to bringing computation to the data, rather than vice versa, offering a secure and controlled environment for handling valuable research assets.
Source: https://www.diraq.com/newsdesk/a-better-way-to-fail-quantum-computing-and-drug-discoverynbsp
